Immune checkpoint inhibitors in extensive-stage small cell lung cancer.
作者信息
Zhang Tongmei
机构信息
Department of General Medicine, Beijing Chest Hospital, Capital Medical University & Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing, China.
出版信息
J Natl Cancer Cent. 2022 Jul 28;2(3):130-131. doi: 10.1016/j.jncc.2022.07.003. eCollection 2022 Sep.
Abstract
摘要
相似文献
1
Immune checkpoint inhibitors in extensive-stage small cell lung cancer.广泛期小细胞肺癌中的免疫检查点抑制剂
J Natl Cancer Cent. 2022 Jul 28;2(3):130-131. doi: 10.1016/j.jncc.2022.07.003. eCollection 2022 Sep.
2
Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.免疫相关不良反应对免疫检查点抑制剂治疗广泛期小细胞肺癌患者生存结局的影响。
Cancer Med. 2024 Apr;13(8):e7188. doi: 10.1002/cam4.7188.
3
Efficacy and Safety of Amrubicin in Small Cell Carcinoma Previously Treated with Immune Checkpoint Inhibitors and Chemotherapy.氨柔比星在既往接受免疫检查点抑制剂和化疗的小细胞癌中的疗效和安全性。
Cancers (Basel). 2022 Aug 16;14(16):3953. doi: 10.3390/cancers14163953.
4
Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.延长生存：免疫检查点抑制剂在广泛期小细胞肺癌治疗中的作用。
Oncologist. 2020 Nov;25(11):981-992. doi: 10.1634/theoncologist.2020-0193. Epub 2020 Sep 23.
5
First-line immune checkpoint inhibitors for extensive stage small-cell lung cancer: clinical developments and future directions.广泛期小细胞肺癌的一线免疫检查点抑制剂：临床进展和未来方向。
ESMO Open. 2021 Feb;6(1):100003. doi: 10.1016/j.esmoop.2020.100003. Epub 2021 Jan 13.
6
Real-world utilization of immune checkpoint inhibitors in extensive stage small-cell lung cancer in community settings.免疫检查点抑制剂在社区环境中广泛期小细胞肺癌的真实世界应用情况。
Immunotherapy. 2023 Nov;15(16):1375-1387. doi: 10.2217/imt-2023-0073. Epub 2023 Sep 11.
7
Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis.一线免疫检查点抑制剂联合化疗治疗广泛期小细胞肺癌的疗效和安全性：一项网状Meta分析。
Lung Cancer. 2023 Apr;178:47-56. doi: 10.1016/j.lungcan.2023.02.003. Epub 2023 Feb 4.
8
Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review.免疫疗法与标准化疗治疗广泛期小细胞肺癌的比较：系统评价。
Immunotherapy. 2021 Aug;13(12):989-1000. doi: 10.2217/imt-2020-0284. Epub 2021 Jun 11.
9
Efficacy and safety analysis of anlotinib in combination with immune checkpoint inhibitors for second-line and subsequent extensive-stage small-cell lung cancer.安罗替尼联合免疫检查点抑制剂二线及后线广泛期小细胞肺癌的疗效及安全性分析。
Neoplasma. 2024 Jun;71(3):297-305. doi: 10.4149/neo_2024_231104N572.
10
[Comparison of efficacy and safety between domestic immune checkpoint inhibitors and pembrolizumab in the treatment of driver gene-negative advanced non-small cell lung cancer].国产免疫检查点抑制剂与帕博利珠单抗治疗驱动基因阴性晚期非小细胞肺癌的疗效及安全性比较
Zhonghua Yi Xue Za Zhi. 2024 Jan 23;104(4):282-289. doi: 10.3760/cma.j.cn112137-20230512-00775.
引用本文的文献
1
Serum zinc as a biomarker to predict the efficacy of immune checkpoint inhibitors in cancers.血清锌作为预测免疫检查点抑制剂对癌症疗效的生物标志物。
PLoS One. 2025 Jul 3;20(7):e0326057. doi: 10.1371/journal.pone.0326057. eCollection 2025.
2
SEC61G Facilitates Brain Metastases via Antagonizing PGAM1 Ubiquitination and Immune Microenvironment Remodeling in Non-Small Cell Lung Cancer.SEC61G通过拮抗非小细胞肺癌中PGAM1的泛素化和免疫微环境重塑促进脑转移。
Int J Biol Sci. 2025 Jan 27;21(4):1436-1458. doi: 10.7150/ijbs.109187. eCollection 2025.
3
Efficacy and safety of novel immune checkpoint inhibitor-based combinations versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer: A network meta-analysis.新型免疫检查点抑制剂联合治疗与化疗作为广泛期小细胞肺癌一线治疗的疗效和安全性：一项网络荟萃分析。
Thorac Cancer. 2024 May;15(15):1246-1262. doi: 10.1111/1759-7714.15310. Epub 2024 Apr 16.
4
Multi-omics profiles refine L-dopa decarboxylase (DDC) as a reliable biomarker for prognosis and immune microenvironment of clear cell renal cell carcinoma.多组学图谱将左旋多巴脱羧酶（DDC）优化为透明细胞肾细胞癌预后和免疫微环境的可靠生物标志物。
Front Oncol. 2022 Dec 5;12:1079446. doi: 10.3389/fonc.2022.1079446. eCollection 2022.
5
Identification of adenylate cyclase 2 methylation in bladder cancer with implications for prognosis and immunosuppressive microenvironment.膀胱癌中腺苷酸环化酶2甲基化的鉴定及其对预后和免疫抑制微环境的影响
Front Oncol. 2022 Oct 14;12:1025195. doi: 10.3389/fonc.2022.1025195. eCollection 2022.
本文引用的文献
1
Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.阿得贝利单抗或安慰剂联合卡铂和依托泊苷一线治疗广泛期小细胞肺癌（CAPSTONE-1）：一项多中心、随机、双盲、安慰剂对照的 3 期临床试验。
Lancet Oncol. 2022 Jun;23(6):739-747. doi: 10.1016/S1470-2045(22)00224-8. Epub 2022 May 13.
2
Small-cell lung cancer.小细胞肺癌。
Nat Rev Dis Primers. 2021 Jan 14;7(1):3. doi: 10.1038/s41572-020-00235-0.
3
Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.帕博利珠单抗或安慰剂联合依托泊苷和铂类药物作为广泛期小细胞肺癌一线治疗：随机、双盲、III 期 KEYNOTE-604 研究。
J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29.
4
Immunotherapeutic approaches for small-cell lung cancer.小细胞肺癌的免疫治疗方法。
Nat Rev Clin Oncol. 2020 May;17(5):300-312. doi: 10.1038/s41571-019-0316-z. Epub 2020 Feb 13.
5
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.度伐利尤单抗联合铂类依托泊苷与铂类依托泊苷一线治疗广泛期小细胞肺癌（CASPIAN）：一项随机、对照、开放标签、III 期临床试验。
Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.
6
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer.阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌。
N Engl J Med. 2018 Dec 6;379(23):2220-2229. doi: 10.1056/NEJMoa1809064. Epub 2018 Sep 25.
7
A plan of attack for deadly cancers.致命癌症的攻坚计划。
Cancer Discov. 2014 Sep;4(9):980. doi: 10.1158/2159-8290.CD-NB2014-114. Epub 2014 Jul 24.
8
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.一项III期研究，比较顺铂加吉西他滨与顺铂加培美曲塞用于初治晚期非小细胞肺癌患者的化疗效果。
J Clin Oncol. 2008 Jul 20;26(21):3543-51. doi: 10.1200/JCO.2007.15.0375. Epub 2008 May 27.
Zotero 插件